经导管二尖瓣修复治疗功能性二尖瓣反流的证据评估
本文由美国国家心肺血液研究所召集跨学科专家研讨会,评估两项2018年发表的经导管二尖瓣修复治疗心力衰竭伴显著功能性二尖瓣反流试验(COAPT与MITRA-FR)结果不一致的原因。文章综述证据强度、试验设计差异、伦理与实施意义,并指出未来研究方向以指导该疗法的合理推广。
要点
- 经导管修复对合适的功能性二尖瓣反流患者可显著减少心衰住院、改善生存与生活质量。
- 成功的关键在于跨学科心脏团队进行术前评估、管理和术后护理。
- 需在真实世界中扩大证据基础,并通过随机或观察性研究比较有效性。
核心结论
- 经导管修复功能性二尖瓣反流在选定患者中可带来显著获益,但证据基础需扩大以优化该复杂疗法的实施。
研究设计与样本
- 美国国家心肺血液研究所召集跨学科专家研讨会,综述两项2018年发表的经导管二尖瓣修复试验(COAPT与MITRA-FR)并评估证据。
主要发现
- 两项试验结果不一致,本文分析了证据强度、试验设计差异、伦理与实施意义。
- 经导管修复可显著减少心衰住院、改善生存与生活质量,前提是识别出接受最佳指南导向药物治疗的中重度或重度二尖瓣反流合适心衰候选者。
- 术前评估与管理及术后护理由跨学科心脏团队完成是成功的关键要素。
临床怎么用
- 应由跨学科心脏团队对合适的心衰伴功能性二尖瓣反流患者进行术前评估、管理和术后护理。
- 需在真实世界中对所有合格候选者(无论是否接受该疗法)完整采集结局数据以优化实施。
- 鉴于治疗交付差异大,应开展实施研究以明确最佳 care 模式的特征。
局限性
- 两项试验结果存在不一致,证据基础需扩大。
- 需要更多随机试验或观察性研究进行比较有效性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Two trials (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation Trial and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation Trial) were published in 2018 evaluating the effectiveness and safety of transcatheter repair for patients with heart failure with significant functional mitral regurgitation, which yielded different results. This article reviews the strength of the evidence, differences in trial designs, ethical and implementation implications, and delineates future research needs to help guide the appropriate dissemination of transcatheter repair for functional patients with mitral regurgitation. METHODS: The National Heart, Lung, and Blood Institute convened a workshop of interdisciplinary experts to address these objectives. RESULTS: Transcatheter repair of functional mitral regurgitation can provide significant benefits in terms of heart failure hospitalizations, survival, and quality of life when appropriate heart failure candidates with moderate to severe or severe mitral regurgitation while on optimal guideline-directed medical therapy can be identified. Key ingredients for success are preoperative evaluation and management and postoperative care by an interdisciplinary heart team. CONCLUSIONS: Given the discordance observed between trials, ongoing innovation in patient management, and potential expansion of indications for use, the evidence base must be expanded to optimize appropriate implementation of this complex therapy. This will require more complete capture of outcome data in real-world settings for all eligible candidates whether or not they receive this therapy. Inevitably, the indications for use of this therapy will expand, as will the devices and therapeutic approaches for this population, necessitating the study of comparative effectiveness through randomized trials or observational studies. Moreover, given the substantial variations in care delivery, conducting implementation research to delineate characteristics of the optimal care model would be of benefit.
引用
- Gelijns AC, Moskowitz AJ, O'Gara PT, et al. Transcatheter mitral valve repair for functional mitral regurgitation: Evaluating the evidence. J Thorac Cardiovasc Surg. 2020. PMID: 32359794. doi:10.1016/j.jtcvs.2020.02.132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。